Abstract
COLLOSS®and COLLOSS® E are bone void fillers consisting of lyophilized type I collagen and non-collagenous proteins extracted with chaotropic solvents from acid demineralized bovine and equine bone, respectively. The protein extracts are precipitated and further purified by methods similar to those used for isolating bone morphogenetic proteins1. COLLOSS® achieved the same rate and percentage of new bone formation as autologous bone graft in a porcine anterior spinal fusion model2 and both COLLOSS® and COLLOSS® E were equal osteoinductive than autograft bone in a sheep cortical bone defect model3. This osteoinductive activity was thought to be most likely mediated by BMPs, because an earlier study had shown that COLLOSS® enclosed in titanium mesh and implanted subcutaneously in rats, induced bone formation4. In this study we used histology and histomorphometry to confirm those results and to better define the osteoinductive potency and the phenotypic diversity of ectopic skeletal tissues induced in weanling Long Evans rats by COLLOSS® and COLLOSS® E. Osteoinduction in response to those materials was compared with induction of bone in response to known amounts of a purified mixture of bovine bone BMPs, GFm.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
6.8. References
Urist MR. Bone Morphogenetic Protein Composition. patent 4,619,989. 1986.
Li H, Zou X, Woo C, Ding M, Lind M, Bunger C. Experimental anterior lumbar interbody fusion with an osteoinductive bovine bone collagen extract. Spine 2005; 30(8):890–896.
Huffer WE, Benedict JJ, Turner AS, Laib. A., Briest A, Rettenmaier R. Repair of sheep long bone cortical defects filled with COLLOSS, COLLOSS E, OSSAPLAST, and fresh iliac autografts. Biomaterials (submitted).
Walboomers XF, Jansen JA. Bone tissue induction, using a COLLOSS-filled titanium fiber meshscaffolding material. Biomaterials 2005; 26(23):4779–4785.
Urist MR. Bone formation by autoinduction. Science 1965; 150:893–899.
Wozney JM, Rosen V, Celeste AJ, Mitsock LM, Whitters MJ, Kriz RW et al. Novel regulators of bone formation: molecular clones and activities. Science 1988; 242(4885):1528–1534.
Wozney JM. The bone morphogenetic protein family: multifunctional cellular regulators in the embryo and adult. [Review] [44 refs]. European Journal of Oral Sciences 1998; 106 Suppl 1:160–166.
Hoffmann A, Weich HA, Gross G, Hillmann G. Perspectives in the biological function, the technical and therapeutic application of bone morphogenetic proteins. Appl Microbiol Biotechnol 2001; 57(3):294–308.
Hogan LM. Bone morphogenetic proteins: multifunctional regulators of vertebrate development. Genes & Development 10, 1580–1594. 1996. Ref Type: Generic
Bahamonde ME, Lyons KM. BMP3: to be or not to be a BMP. J Bone Joint Surg Am 2001; 83-ASuppl 1(Pt 1):S56–S62.
Helm GA, Li JZ, Alden TD, Hudson SB, Beres EJ, Cunningham M et al. A light and electron microscopic study of ectopic tendon and ligament formation induced by bone morphogenetic protein-13 adenoviral gene therapy. J Neurosurg 2001; 95(2):298–307.
Wozney JM. Overview of bone morphogenetic proteins. Spine 2002; 27(16 Suppl 1):S2–S8.
Poser JW, Benedict JJ. Intermedics Orthopedics/Denver Inc.Wheat Ridge C, editor. Osteoinducitve protein mixture and purification processes. patent 5290763. 1994.
Roethy W, Fiehn E, Suehiro K, Gu A, Yi GH, Shimizu J et al. A growth factor mixture that significantly enhances angiogenesis in vivo. J Pharmacol Exp Ther 2001; 299(2):494–500.
Seeherman H, Wozney J, Li R. Bone morphogenetic protein delivery systems. Spine 2002; 27(16 Suppl 1):S16–S23.
Sampath TK, Reddi AH. Dissociative extraction and reconstitution of extracellular matrix components involved in local bone differentiaton. Proc Natl Acad Sci USA 1981; 78:7599–7602.
Sampath T.K., Reddi AH. Homology of bone-inductive proteins from human, monkey, bovine, and rat extracellular matrix. Proc Natl Acad Sci USA 1983; 80(21):6591–6595.
Bertagnoli R. Osteoinductive bone regeneration substance Colloss in spinal fusion. European Spine Journal 11, 189–190. 2002. Ref Type: Generic
Cornell CN. Initial clinical experience with the use of Collagraft as a bone graft substitute. Techniques Orth 1992; 7(2):55–63.
Feifel H. [Bone regeneration in Pro Osteon 500 alone and in combination with Colloss in the patellar gliding model of the rabbit]. Mund Kiefer Gesichtschir 2000; 4Suppl 2:S527–S530.
Kloss FR, Schlegel KA, Felszeghy E, Falk S, Wiltfang J. [Applying an osteoinductive protein complex for regeneration of osseous defects]. Mund Kiefer Gesichtschir 2004; 8(1):12–17.
Schlegel KA, Kloss FR, Kessler P, Schultze-Mosgau S, Nkenke E, Wiltfang J. Bone conditioning to enhance implant osseointegration: an experimental study in pigs. Int J Oral Maxillofac Implants 2003; 18(4):505–511.
Wiltfang J, Kloss FR, Kessler P, Nkenke E, Schultze-Mosgau S, Zimmermann R et al. Effects of plateletrich plasma on bone healing in combination with autogenous bone and bone substitutes in critical-size defects. An animal experiment. Clin Oral Implants Res 2004; 15(2):187–193.
Huffer WE, Lewis M, Barnes T, Benedict JJ. Strategies for tailoring bone and connective tissue regeneration using bone protein. In: Davies JE, editor. Bone Engineering: An International Workshop. Toronto: University of Toronto Press, 2001: 408–420.
Sasano Y, Ohtani E, Narita K, Kagayama M, Murata M, Saito T et al. BMPs induce direct bone formation in ectopic sites independent of the endochondral ossification in vivo. Anat Rec 1993; 236(2):373–380.
Stoeger T, Proetzel GE, Welzel H, Papadimitriou A, Dony C, Balling R et al. In situ gene expression analysis during BMP2-induced ectopic bone formation in mice shows simultaneous endochondral and intramembranous ossification. Growth Factors 2002; 20(4):197–210.
Nakagawa T, Tagawa T. Ultrastructural study of direct bone formation induced by BMPs-collagen complex implanted into an ectopic site. Oral Dis 2000; 6(3):172–179.
Aono A, Hazama M, Notoya K, Taketomi S, Yamasaki H, Tsukuda R et al. Potent ectopic bone-inducing activity of bone morphogenetic protein-4/7 heterodimer. Biochem Biophys Res Commun 1995; 210(3):670–677.
Kuboki Y, Jin Q, Kikuchi M, Mamood J, Takita H. Geometry of artificial ECM: sizes of pores controlling phenotype expression in BMP-induced osteogenesis and chondrogenesis. Connect Tissue Res 2002; 43(2–3):529–534.
Takita H, Kikuchi M, Sato Y, Kuboki Y. Inhibition of BMP-induced ectopic bone formation by an antiangiogenic agent (epigallocatechin 3-gallate). Connect Tissue Res 2002; 43(2–3):520–523.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Science+Business Media, LLC
About this paper
Cite this paper
Huffer, W.E., Benedict, J.J., Rettenmaier, R., Briest, A. (2006). Osteoinduction with Colloss®, Colloss® E, and GFm. In: Fisher, J.P. (eds) Tissue Engineering. Advances in Experimental Medicine and Biology, vol 585. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-34133-0_6
Download citation
DOI: https://doi.org/10.1007/978-0-387-34133-0_6
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-32664-1
Online ISBN: 978-0-387-34133-0
eBook Packages: EngineeringEngineering (R0)